Cahill Represents Initial Purchasers in $1 Billion Notes Offering for Valeant Pharmaceuticals International, Inc.
Date: 10/17/17
Cahill represented the initial purchasers in connection with the Rule 144A offering of $1,000,000,000 in aggregate principal amount of 5.5% senior secured notes due 2025 by Valeant Pharmaceuticals International, Inc. Proceeds from the offering are expected to be used for refinancing existing indebtedness.